FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955109223> ?p ?o ?g. }

• W2955109223 endingPage "iv91" @default.
• W2955109223 startingPage "iv91" @default.
• W2955109223 abstract "Introduction: Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide. Over the last two decades, median overall survival (OS) for patients with metastatic CRC (mCRC) has increased to roughly 30 months due to the improvements in number and efficacy of systemic therapies. Recently, two novel drugs have been approved for the treatment of chemorefractory mCRC patients such as Regorafenib and Trifluridine/Tipiracil (TAS-102). However, despite their clinical approval, it still remains unclear which of these two drugs should be used first because of lack of head-to-head randomized trials. Methods: We have compared retrospectively the safety and efficacy between regorafenib and Tas-102 in patients with mCRC refractory to standard therapies who had access to both drugs at a single institution between January 2018 and February 2019, in a clinical practice setting. The progression-free survival (PFS) and overall survival (OS) were compared using a log-rank test with 95% confidence intervals (95% CIs) Results: Forty-six patients with mCRC treated with regorafenib or TAS102, in a clinical practice setting, after failure of standard therapies including fluoropyrimidine, oxaliplatin, irinotecan, anti-VEGF therapy and anti-EGFR agents in RAS wild type were included in the analysis. In particular, among them 25 patients were treated for the first time (primary treatment) with regorafenib whereas 21 patients were treated with TAS-102. Of these patients, 20 patients switched to crossover treatment. In particular, 12 went on to receive TAS-102 and 8 went on to receive regorafenib as secondary treatment. Baseline demographic and disease characteristics were well balanced between the two groups in terms of the primary treatment. No patient had complete response (CR) or partial response (PR). The median OS was 15 months for regorafenib and 15.2 months for TAS-102 and the corresponding values after crossover were 5.4 and 5.1 months respectively. Median PFS1 defined as the interval from the first administration of the primary treatment to the first radiological progression or death from any cause, whichever come first, was 4.2 months for regorafenib and 4 months for TAS-102. However, median PFS2 defined as the interval from the initiation of secondary treatment to secondary progression, for those who had undertaken crossover treatments after first progression was 4.7 months for regorafenib and 3.3 months for TAS-102. No unexpected adverse events (AEs) were found compared with previously reported data. Moreover, AEs were tolerable even after the crossover. Conclusion: No significant difference between regorafenib and TAS-102 sequence treatments was observed in patients with mCRC. Further analyses are ongoing to potentially identify a biomarker to distinguish the two drugs." @default.
• W2955109223 created "2019-07-12" @default.
• W2955109223 creator A5002124283 @default.
• W2955109223 creator A5006208754 @default.
• W2955109223 creator A5011531470 @default.
• W2955109223 creator A5013734061 @default.
• W2955109223 creator A5022869270 @default.
• W2955109223 creator A5027193970 @default.
• W2955109223 creator A5029026296 @default.
• W2955109223 creator A5047539709 @default.
• W2955109223 creator A5048947412 @default.
• W2955109223 creator A5050411971 @default.
• W2955109223 creator A5074412985 @default.
• W2955109223 creator A5076690603 @default.
• W2955109223 creator A5080766681 @default.
• W2955109223 creator A5081145094 @default.
• W2955109223 creator A5082156303 @default.
• W2955109223 creator A5085415520 @default.
• W2955109223 creator A5087739912 @default.
• W2955109223 creator A5088094654 @default.
• W2955109223 date "2019-07-01" @default.
• W2955109223 modified "2023-09-28" @default.
• W2955109223 title "Retrospective study of Regorafenib versus Trifluridine/Tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: a single Italian institution real-life clinical data" @default.
• W2955109223 doi "https://doi.org/10.1093/annonc/mdz155.329" @default.
• W2955109223 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32085343" @default.
• W2955109223 hasPublicationYear "2019" @default.
• W2955109223 type Work @default.
• W2955109223 sameAs 2955109223 @default.
• W2955109223 citedByCount "0" @default.
• W2955109223 crossrefType "journal-article" @default.
• W2955109223 hasAuthorship W2955109223A5002124283 @default.
• W2955109223 hasAuthorship W2955109223A5006208754 @default.
• W2955109223 hasAuthorship W2955109223A5011531470 @default.
• W2955109223 hasAuthorship W2955109223A5013734061 @default.
• W2955109223 hasAuthorship W2955109223A5022869270 @default.
• W2955109223 hasAuthorship W2955109223A5027193970 @default.
• W2955109223 hasAuthorship W2955109223A5029026296 @default.
• W2955109223 hasAuthorship W2955109223A5047539709 @default.
• W2955109223 hasAuthorship W2955109223A5048947412 @default.
• W2955109223 hasAuthorship W2955109223A5050411971 @default.
• W2955109223 hasAuthorship W2955109223A5074412985 @default.
• W2955109223 hasAuthorship W2955109223A5076690603 @default.
• W2955109223 hasAuthorship W2955109223A5080766681 @default.
• W2955109223 hasAuthorship W2955109223A5081145094 @default.
• W2955109223 hasAuthorship W2955109223A5082156303 @default.
• W2955109223 hasAuthorship W2955109223A5085415520 @default.
• W2955109223 hasAuthorship W2955109223A5087739912 @default.
• W2955109223 hasAuthorship W2955109223A5088094654 @default.
• W2955109223 hasBestOaLocation W29551092231 @default.
• W2955109223 hasConcept C121608353 @default.
• W2955109223 hasConcept C126322002 @default.
• W2955109223 hasConcept C143998085 @default.
• W2955109223 hasConcept C2776248978 @default.
• W2955109223 hasConcept C2776694085 @default.
• W2955109223 hasConcept C2780259306 @default.
• W2955109223 hasConcept C2780739268 @default.
• W2955109223 hasConcept C2780962732 @default.
• W2955109223 hasConcept C526805850 @default.
• W2955109223 hasConcept C535046627 @default.
• W2955109223 hasConcept C71924100 @default.
• W2955109223 hasConceptScore W2955109223C121608353 @default.
• W2955109223 hasConceptScore W2955109223C126322002 @default.
• W2955109223 hasConceptScore W2955109223C143998085 @default.
• W2955109223 hasConceptScore W2955109223C2776248978 @default.
• W2955109223 hasConceptScore W2955109223C2776694085 @default.
• W2955109223 hasConceptScore W2955109223C2780259306 @default.
• W2955109223 hasConceptScore W2955109223C2780739268 @default.
• W2955109223 hasConceptScore W2955109223C2780962732 @default.
• W2955109223 hasConceptScore W2955109223C526805850 @default.
• W2955109223 hasConceptScore W2955109223C535046627 @default.
• W2955109223 hasConceptScore W2955109223C71924100 @default.
• W2955109223 hasLocation W29551092231 @default.
• W2955109223 hasOpenAccess W2955109223 @default.
• W2955109223 hasPrimaryLocation W29551092231 @default.
• W2955109223 hasRelatedWork W1963973664 @default.
• W2955109223 hasRelatedWork W1965063355 @default.
• W2955109223 hasRelatedWork W2037724349 @default.
• W2955109223 hasRelatedWork W2050348440 @default.
• W2955109223 hasRelatedWork W2069668461 @default.
• W2955109223 hasRelatedWork W2086707902 @default.
• W2955109223 hasRelatedWork W2127366124 @default.
• W2955109223 hasRelatedWork W2577979650 @default.
• W2955109223 hasRelatedWork W2940357394 @default.
• W2955109223 hasRelatedWork W3142077694 @default.
• W2955109223 hasVolume "30" @default.
• W2955109223 isParatext "false" @default.
• W2955109223 isRetracted "false" @default.
• W2955109223 magId "2955109223" @default.
• W2955109223 workType "article" @default.